在LUAD中,IGF2BP3-TRIM37-P53轴促进瘤进展
Ting Ji1, Tingting Zhao1, Shuni Wang2
1Ningxia Key Laboratory of Clinical and Pathogenic Microorganisms, Institute of Medical Science, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China; Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China.
胰岛素样生长因子2 mRNA结合蛋白3 (IGF2BP3) 通过稳定TRIM37 mRNA促进肺腺癌 (LUAD),导致p53蛋白降解. 沉默TRIM37可以抑制LUAD的进展,提供治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- N6-甲基氨酸 (m6A) 和泛化修饰是肺腺癌 (LUAD) 进展的关键驱动因素.
- 这些修改与细胞环境密切相关,包括p53状态.
- 了解这些修饰如何调节LUAD中的p53对于开发向疗法至关重要.
研究的目的:
- 为了研究IGF2BP3的作用,一个关键的m6A调节器,在LUAD的发病.
- 阐明IGF2BP3影响p53状态和LUAD进展的机制.
- 根据IGF2BP3-TRIM37-p53轴来确定LUAD的潜在治疗点.
主要方法:
- 利用TCGA数据选IGF2BP3并评估其在LUAD中的表达和生存相关性.
- 进行了殖民地形成和CCK8测试,以评估IGF2BP3对细胞增殖的影响.
- 利用GEO数据的生物信息学分析来确定TRIM37作为IGF2BP3.3的下游目标.
- 通过使用RIP-qPCR,通过IGF2BP3确认TRIM37mRNA的m6A丰富.
- 在体外和体内验证了IGF2BP3的前瘤效应.
主要成果:
- 发现IGF2BP3在LUAD中表达很高,与患者预后不佳相关.
- 鉴定出IGF2BP3是一种m6A阅读器,它与TRIM37mRNA的3'UTR结合,稳定其表达.
- 通过ubiquitination,TRIM37被证明可以促进p53蛋白质降解.
- 在体外和体外模型中,沉默TRIM37有效地逆转了IGF2BP3促进瘤的作用.
结论:
- IGF2BP3通过作为m6A阅读器来促进LUAD细胞的增殖.
- 从机制上讲,IGF2BP3通过与m6A修饰的TRIM37mRNA结合,促进p53的泛化和降解,从而推动LUAD瘤发生.
- 向TRIM37 (shTRIM37) 显著抑制了IGF2BP3驱动的瘤进展,突出了其治疗潜力.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
